Sensorion to Present GJB2-GT Research at ESGCT Congress 2024 Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of innovative therapies for hearing loss, has announced its participation in the 31st Congress of the European Society…
Insights on Consumer Attitudes Toward Healthy, Sustainable Food Systems The FoodMinds 2024 Conscious Consumption Index (CCI) reveals a growing awareness of healthy and sustainable food systems among consumers. Despite this awareness, less than half (42%) of surveyed individuals report purchasing…
Nielsen IQ (NIQ), the leading consumer research and retail monitoring firm, has unveiled its mid-year Consumer Outlook report, revealing a significant shift in Asia-Pacific consumer behavior towards purposeful consumption. This trend mirrors a global movement as consumers become more conscious…
As CarePlus celebrates its 25th anniversary, the Florida-based Medicare Advantage provider is enhancing its plans for 2025, focusing on affordable healthcare and financial wellness. The new offerings aim to improve health outcomes across the state, featuring robust subsidies, $0 copays,…
Eisai’s Rozebalamin® for Injection 25 mg Wins Good Design Award 2024 for Light-Proof Vial Packaging Eisai Co., Ltd. (Tokyo, CEO: Haruo Naito) announced that its amyotrophic lateral sclerosis (ALS) treatment, Rozebalamin® for Injection 25 mg (mecobalamin), has received the 2024…
Lupin Launches First Generic Pred Forte® Ophthalmic Suspension in the U.S. Prednisolone Acetate Ophthalmic Suspension Marks First Generic Launch with 180-Day CGT Exclusivity Mumbai, Naples, October 15, 2024: Lupin Limited, a global pharmaceutical company, announced the launch of the first…
bit.bio has successfully defended its European patent for the groundbreaking opti-ox™ technology, which facilitates the precise programming of pluripotent stem cells (PSCs), including induced pluripotent stem cells (iPSCs), into any human cell type. The European Patent Office (EPO) upheld bit.bio’s…
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing innovative treatments for seizure disorders, announced the addition of a new patent to its intellectual property portfolio. The United States Patent and Trademark Office (USPTO) has granted a patent for…
GSK plc (LSE/NYSE: GSK) has announced new findings from the AReSVi-006 Phase III trial, which assessed the effectiveness of a single dose of Arexvy, a recombinant adjuvanted vaccine for respiratory syncytial virus (RSV), against lower respiratory tract disease (LRTD) in…
Pfizer Inc. (NYSE: PFE) has announced encouraging topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study, evaluating TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway…
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, announced plans to present new research at IDWeek 2024 in Los Angeles, CA, from October 16-19. The company will showcase the latest findings on its expanding vaccines and…
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced that argenx has identified four new targets under their global collaboration and license agreement. This agreement grants argenx exclusive access to Halozyme’s ENHANZE® drug delivery technology, which utilizes the proprietary recombinant human hyaluronidase…
